Search results
Results from the WOW.Com Content Network
Multidisciplinary Association for Psychedelic Studies; Abbreviation: MAPS Established: 1986 (39 years ago) Founders: Rick Doblin Types: nonprofit organization Legal status: 501(c)(3) organization Country: United States Revenue: 23,580,425 United States dollar (2021) Total Assets: 92,188,866 United States dollar (2021) Website: maps.org
Lykos Therapeutics, formerly known as the MAPS Public Benefit Corporation (MAPS PBC), is a public benefit corporation (PBC) that is developing MDMA ("ecstasy") as a potential medicine. [1] It was founded and is considerably owned by the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS). [ 1 ]
Their business operates illegally, as sale and possession of magic mushrooms is illegal in Canada. [3] These stores are frequently raided and their products confiscated. [ 4 ] [ 5 ] [ 6 ] The raided stores usually reopen quickly after the seized merchandise has been replaced, [ 7 ] with the exception of the five locations that have been ...
MAPS was founded in 1986 to oppose a federal decision placing MDMA in the same ultra-restrictive drug category as heroin, LSD and other illegal psychedelics. MAPS' studies of MDMA began more than ...
[1] [3] [2] Psychedelic mushroom stores are also known to operate online in the United States and Canada. [5] Numerous stores were prevalent in the United Kingdom in the 2000s when a legal loophole allowed magic mushrooms to be sold, [6] but the loophole was closed in 2005 and the products stopped being sold.
Federal health regulators are questioning the safety and evidence behind the first bid to use MDMA, the mind-altering club drug, as a treatment for PTSD, part of a decadeslong effort by advocates ...
The Multidisciplinary Association for Psychedelic Studies (MAPS) is conducting studies in the psychedelic treatment of post-traumatic stress disorder. The Phase 2 trials of these studies, conducted in the U.S., Canada, and Israel, consisted of 107 participants who had chronic, treatment-resistant PTSD, and had had PTSD for an average of 17.8 ...
Midomafetamine (MDMA; "ecstasy") – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT 2A, 5-HT 2B, 5-HT 2C receptor agonist, entactogen, and weak psychedelic hallucinogen – post-traumatic stress disorder, alcoholism, social anxiety in autism – Multidisciplinary Association for Psychedelic Studies (MAPS), Lykos ...